Lundbeck's Rexulti Growth Hopes Clouded By Dementia Agitation Data Setback
Executive Summary
Denmark-based Lundbeck's plans to make Rexulti the first approved drug for agitation associated with dementia have been knocked back by mixed clinical data, necessitating another Phase III trial.
You may also be interested in...
CNS 'Graveyard Of Drug Development' Needs Oncology-Like FDA Regulatory Approach
Lundbeck executive calls for adaptive trial designs, transdiagnostic approach, and more scientific discussions between sponsors and the US Food and Drug Administration.
Otsuka’s Avanir Encouraged By First Peek At Treatment For Alzheimer’s Agitation
Phase III results from Avanir’s candidate for agitation in patients with Alzheimer’s disease offers some hope in a setting for which there is no specific treatment.
Pressure Builds On Lundbeck After Rexulti Fails In Bipolar I Manic Episodes
Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.